| Product Code: ETC7659480 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Industry Life Cycle |
3.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Porter's Five Forces |
3.5 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Drugs Type, 2021 & 2031F |
3.6 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Indication Type, 2021 & 2031F |
3.7 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in Israel |
4.2.2 Growing adoption of precision medicine in cancer treatment |
4.2.3 Rising investments in research and development of PARP inhibitors |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval in Israel |
4.3.2 High cost associated with PARP inhibitor drugs |
4.3.3 Limited awareness among healthcare professionals and patients about PARP inhibitors |
5 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Trends |
6 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Types |
6.1 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Drugs Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Drugs Type, 2021- 2031F |
6.1.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Talazoparib, 2021- 2031F |
6.1.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Veliparib, 2021- 2031F |
6.1.5 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Olaparib, 2021- 2031F |
6.1.6 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Indication Type |
6.2.1 Overview and Analysis |
6.2.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.2.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Fallopian Tube Cancer, 2021- 2031F |
6.2.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.5 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.5 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
7 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Import-Export Trade Statistics |
7.1 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Export to Major Countries |
7.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Imports from Major Countries |
8 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Key Performance Indicators |
8.1 Number of clinical trials testing PARP inhibitors in Israel |
8.2 Adoption rate of PARP inhibitors in cancer treatment |
8.3 Investment trends in Israeli biotech companies developing PARP inhibitors |
9 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Opportunity Assessment |
9.1 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Drugs Type, 2021 & 2031F |
9.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Indication Type, 2021 & 2031F |
9.3 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Competitive Landscape |
10.1 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 Israel Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here